<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310593</url>
  </required_header>
  <id_info>
    <org_study_id>63811317300005327</org_study_id>
    <nct_id>NCT03310593</nct_id>
  </id_info>
  <brief_title>Cannabidiol as an Adjunctive Treatment for Bipolar Depression</brief_title>
  <acronym>CBDBD</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled Clinical Trial of Adjunctive Cannabidiol for Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depressive symptoms are associated with significant psychosocial impairment. However, current
      treatments of bipolar depression are only partially effective.

      Cannabidiol is a natural component of cannabis without psychotomimetic or addictive
      properties. Cannabidiol has been shown to produce therapeutic effects including
      anticonvulsive, anxiolytic, antipsychotic and neuroprotective effects. The investigators
      hypothesize that treatment with cannabidiol will result in improvement of depressive and
      anxiety symptoms, as well as, improvement in functioning and inflammatory biomarkers. During
      the clinical trial subjects will receive study medications (cannabidiol 600mg/day or placebo)
      for a period of 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized and placebo controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Montgomery-Asberg Depression Rating Scale (MADRS) scores.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change from baseline Montgomery-Asberg Depression Rating Scale (MADRS) scores.
Scale range: from 0 to 60.
Higher values represent more severe symptoms of depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in clinical global impression.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change from baseline in Clinical Global Impression(CGI-BP) scores.
Scale range: from 1 to 7.
Higher values represent more severe symptoms of bipolar disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in anxiety symptoms</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change from baseline in Hamilton Anxiety Rating Scale (HAMA).
Scale range: from 0 to 56.
Higher values represent more severe symptoms of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in functioning.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change from baseline Functioning Assessment Short Test (FAST) scores.
Scale range: from 0 to 72.
Higher values represent more severe functional impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in biological rhythms.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Improvement in biological rhythms according to Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN).
Scale range: from 0 to 88.
Higher values represent more severe symptoms of biological rhythms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BDNF levels in the blood.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change in brain-derived neurotrophic factor (BDNF) levels in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory levels in the blood.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change in inflammatory levels in the blood (cytokines, chemokines and C-reactive protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endocannabinoid levels in the blood.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change in endocannabinoid levels in the blood.(anandamide and 2-arachidonoylglycerol).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission of manic symptoms.</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change from baseline in the Young Mania Rating Scale (YMRS) score.
Scale range: from 0 to 58.
Higher values represent more severe symptoms of mania.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depressive symptoms</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change from baseline in Hamilton Depression Rating Scale (HAMD) score.
Scale range: from 0 to 52.
Higher values represent more severe symptoms of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychotic symptoms</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change from baseline in Brief Psychiatric Rating Scale (BPRS) score.
Scale range: from 0 to 108.
Higher values represent more severe symptoms of psychosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depressive symptoms according to PHQ-9</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Change from baseline in Patient Health Questionnaire (PHQ-9) score.
Scale range: from 0 to 27.
Higher values represent more severe symptoms of depression.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Evaluation of side effects according Udvalg for Kliniske Undersogelser (UKU) side effects rating scale.
Scale range: from 0 to 144.
Higher values represent more severe side effects associated to medications.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Bipolar Depression</condition>
  <condition>Bipolar Affective Disorder</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol 300mg per day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cannabidiol comparator for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Cannabidiol as active intervention.</description>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intervention.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depressive episode as part of bipolar I disorder or bipolar II disorder
             according to Fifth Edition of Diagnostic and Statistical Manual for Mental Disorders
             (DSM-5) and are able to provide written informed consent.

          -  Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 12 and MADRS items 1
             (Apparent Sadness) and 2 (Reported Sadness) scores ≥ 2 at baseline.

          -  Young Mania Rating Scale (YMRS) ≤ 11.

          -  Currently prescribed lithium or valproic acid and derivates (divalproex sodium, sodium
             valproate) or atypical antipsychotics at therapeutic dosage for at least 04 weeks
             before the baseline.

          -  Females must test negative for pregnancy and must be using adequate birth control
             measures throughout the study.

        Exclusion Criteria:

          -  Another concurrent mental or behavioral disorder that requires psychiatric attention
             in the past 6 months.

          -  Young Mania Rating Scale (YMRS) score &gt; 12.

          -  Current or past drug sensitivity/intolerance to cannabidiol.

          -  Substance Use Disorder according to DSM-5 within past 6 months, except for nicotine
             Substance Use Disorder.

          -  Clinically significant unstable medical illness, neurological disorders or
             inflammatory/autoimmune diseases.

          -  Any autoimmune, inflammatory or neurologic disorders that requires treatment with
             steroidal anti-inflammatory medications or immunotherapy with biologic drugs.

          -  Actively suicidal or homicidal risk.

          -  Females who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Márcia Kauer-Sant'Anna, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Márcia Kauer-Sant'Anna, MD, PhD</last_name>
    <phone>+55 51 3359 8845</phone>
    <email>mksantanna@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jairo Vinícius Pinto, MD</last_name>
    <phone>+55 51 3359 8021</phone>
    <email>jairovinicius@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Márcia Kauer-Sant'Anna, MD, PhD</last_name>
      <phone>+55 51 3359 8845</phone>
      <email>mksantanna@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jairo Vinícius Pinto, MD</last_name>
      <phone>+55 51 3359 8021</phone>
      <email>jairovinicius@msn.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bipolar disorder</keyword>
  <keyword>bipolar depression</keyword>
  <keyword>cannabidiol</keyword>
  <keyword>endocannabinoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

